Cell line · CVCL_0374
Papers71
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 71
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PD-L1 Expression in Acute Myeloid Leukemia Cells: Associations With Cell Metabolism. | J Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrative multi-omics, machine learning, and experimental validation reveal that TPM1 suppresses M2 macrophage polarization and enhances chemosensitivity in acute myeloid leukemia. | Cell Biol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Energy Deficiency-Induced ATG4B Nuclear Translocation Inhibits PRMT1-Mediated DNA Repair and Promotes Leukemia Progression. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Aberrant expression of human endogenous retrovirus K9-derived elements is associated with better clinical outcome of acute myelocytic leukemia. | Retrovirology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type. | Sci Adv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. | Int J Mol Sci | 2023 | Cellosaurus cites it | PubMed | |
| Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. | Cell Biosci | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0374/papers